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Abstract Huntington’s disease (HD) is a neurodegenerative
disorder characterized by a progressive motor and cognitive
decline and the development of psychiatric symptoms. The
origin of molecular and biochemical disturbances in HD is a
mutation in the HTT gene, which is autosomally dominantly
inherited. The altered huntingtin protein is ubiquitously
expressed in the CNS, as well as in peripheral tissues. In this
study we measured the metabolism changes in gene transcrip-
tion in blood of HD gene carriers (premanifest and manifest
combined) versus 28 healthy controls. The comparison
revealed statistically significant Global Pattern Recognition
Fold Change (FC) for 6 mRNA transcripts, reflecting an in-
crease of: MAOB (FC03.07; p00.0005) which encodes an
outer mitochondrial membrane-bound enzyme called mono-
amine oxidase type B; TGM2 (FC01.8; p00.02) encoding a
transglutaminase 2 that mediates cellular stress; SLC2A4 (FC0
1.64; p00.02) solute carrier family 2 (facilitated glucose trans-
porter) member 4; branched chain ketoacid dehydrogenase
kinase (BCKDK) (FC01.34; p00.02); decrease of LDHA
(FC0−1.16; p00.03) lactate dehydrogenase A; and brain-
derived neurotrophic factor (BDNF) (FC0−2,11; p00.03).
These distinguished changes coincided with HD progress.
The analyses of gene transcription levels in sub-cohorts con-
firmed these changes and also revealed 28 statistically signifi-
cant FCs of gene transcripts involved in ATP production and
BCAA metabolism.
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Introduction
Huntington’s disease (HD) is an autosomal dominant, neuro-
degenerative disorder with no effective treatment (The
Huntington’s Disease Collaborative Research Group 1993;
Perez-De La Cruz and Santamaria 2007). The course of HD
is slow and characterized by a gradual progression of motor,
emotional and cognitive dysfunction leading to speech cessa-
tion, swallowing difficulties, walking problems and finally to
the loss of independence and the whole organism devastation
(Davies and Ramsden 2001; Ross and Tabrizi 2011). CAG
triplet repeat expansion in the first exon of theHTT gene results
in an expansion of the polyglutamine (polyQ) tract in the N-
terminus of the huntingtin protein (HTT) (Atwal et al. 2007);
expansion above 35 polyQ results in the “mutant huntingtin”
(mHTT). The unchanged polyQ tract is an active point of HTT
in binding to other protein partners, but an elongated polyQ
tract leads to the formation of nuclear and cytoplasmic aggre-
gates, confers a gain-of-function as well as a loss-of-function
of huntingtin and causes pathological changes on the cellular
level inside and outside the CNS (Bjorkqvist et al. 2008;
Sathasivam et al. 1999). Both the number of CAG repeats in
the larger allele and epigenetic factors contribute to HD onset
age and disease progression.
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Metabolic abnormalities in HD, including an impairment
of cellular energy production and mitochondrial dysfunc-
tion, result in lower adenosine 5′-triphosphate (ATP) pro-
duction (Chaturvedi et al. 2010; Cui et al. 2006; Liang and
Ward 2006; Milakovic and Johnson 2005; Mochel et al.
2007, 2012; Weydt et al. 2006). Bioenergetics defects lead
to weight loss and muscle wastage despite increased caloric
intake in HD patients (Chaturvedi et al. 2010; Cui et al.
2006; Kosinski et al. 2007; Weydt et al. 2006). In addition, a
systemic metabolic defect is closely related to the low level
of branched chain amino acids (BCAA) in the serum or plasma
of HD patients, which also results in early weight loss
(Chaturvedi et al. 2010; Cui et al. 2006; Kosinski et al. 2007;
Mochel et al. 2007, 2011; Weydt et al. 2006).
The activity of the peroxisome proliferator-activated recep-
tor γ (PPARγ) coactivator 1α (PGC-1α) in human and mouse
HD striatal and motor neurons is reduced due to the mHTT/
HTT related decrease of its transcription level. This reduction
results in impairment of mitochondrial functions (Cui et al.
2006; St-Pierre et al. 2006; Weydt et al. 2006) as PGC-1α, a
transcriptional co-factor, encoded by PPARGC1A gene, plays a
key role regulating the expression of genes responsible for
energy metabolism. It participates in energy homeostasis,
adaptive thermogenesis, β-oxidation of fatty acids, and glu-
cose metabolism by regulating the expression of mitochondrial
OXPHOS genes and endogenous antioxidants (Puigserver et
al. 2003). PGC-1α also regulates the activity of histone deace-
tylase in muscles. Co-localization of HTT and PPARGC1A
genes can influence transcription deregulation and is therefore
considered to play an important role in HD pathogenesis
(Kozlowski et al. 2010; Weydt et al. 2006). Mitochondrial
malfunction in the basal ganglia of HD patients results in
glucose metabolism reduction and lactate increase (Milakovic
and Johnson 2005). Furthermore, biochemical studies revealed
a reduced activity of several key components of oxidative
phosphorylation, including complexes II, III, and IV of the
electron transport chain in the mitochondria of striatal neurons
in HD patients at an advanced stage of the disease (Beal et al.
1993; Browne and Beal 2004).
It is argued that the BCAA level decrease in the sera of HD
subjects contributes to a BMI reduction and accelerates the
disease progression (Mochel et al. 2007, 2011). BCAAs are
involved in the mitochondrial intermediary metabolism as
substrates in tricarboxilic acid (TCA), and their decreased
level may indicate a systemic attempt to compensate for an
early energy deficit in HD (Mochel et al. 2012). Therefore an
identification of molecular changes associated with energy
production and BCAA metabolism at the gene transcription
level could identify biomarkers for the early detection of the
disease as well as potential drug targets for effective therapies.
In this study we focused on energy metabolism pathways
in blood cells in order to evaluate energy metabolism
changes at the gene transcription level, using quantitative
Polymerase Chain Reaction (qPCR), of HD (pre-manifest
and manifest) subjects compared to healthy subjects.
Material and methods
Subjects
Altogether 57 people were included in this study. The HD
group –HDG (n029) consisted of pre-manifest HD (n06) and
manifest HD (n023) subjects and the control group (CG)
comprised healthy subjects (n028). Subject’s key character-
istics are presented in Table 1a and b. All HDG individuals
were confirmed carriers of the HTT gene mutation (ranged
from 38 to 81 CAG (mean 45, SD±15) in the larger allele)
Subjects were also characterized by their body mass index
(BMI), calf circumference (CC; cm), to reflect condition of
muscle mass, and a Mini Nutritional Assessment (MNA)
evaluated the risk of malnutrition. HD motor symptoms were
rated using the Unified Huntington Disease Rating Scale
(UHDRS), and motor and functional impairment were evalu-
ated using the Total Functional Capacity (TFC) assessment.
Subjects were identified using the REGISTRY Database of
European Huntington’s Disease Network. This study was
approved by Bioethical Committee at Poznan University of
Medical Science, Poland on September 03. 2009. Agreement
No, 770/09. All human studies approved by this Agreement
have been performed in accordance with Good Clinical
Practice laid down in the Declaration of Helsinki.
Blood sample collection
Blood samples were collected from fasting (since 6.00 p.m.
of the previous day) subjects between 8 and 10 a.m. General
blood tests required 15 ml and the Tempus collection tube
(with RNA stabilizing buffer) (Applied Biosystems, Foster
City, CA, USA) for total RNA isolation required 3 ml. To
exclude disorders affecting metabolism, general blood tests
of all participants were preformed for blood smear and
morphology, CRP, ESR, triiodothyronine (FT3), tetraiodo-
thyronine (FT4), TSH, cortisol, urea, creatinine, uric acid,
cholesterol, protein fractions pattern and glucose levels.
Total RNA extraction
Total RNAwas isolated using Tempus™ Spin RNA Isolation
Kit (Applied Biosystems, Foster City, CA, USA) according to
the manual instructions. Genomic DNA was eliminated by
treating each sample with RNase-free DNase I (Fermentas
Thermo Fisher Scientific Inc., Vilnius, Lithuania) according
to the manual instructions. The concentration of isolated total
RNA was calculated from absorbance at 260 nm with a
BioPhotometer (Eppendorf, Hamburg, Germany), the purity
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was verified by optical density (OD) absorption ratio OD260 nm/
OD280 nm between 1.60 and 1.8, and OD260 nm/OD230 nm
ranging from 1.8 to 2.00 and the integrity was evaluated by
electrophoresis on Gel – RNA Flash Gel System (Lonza
Rockland Inc., Rockland, ME, USA). Total RNA subunits of
18S and 28S were observed on the gel and absence of smears
indicating minimal degradation of the RNA, RNA template
was suspended in RNase and DNase free water and stored at
−80 °C with RNase inhibitor (Fermentas Thermo Fisher
Scientific Inc, Vilnius, Lithuania).
First strand cDNA synthesis
One microgram RNA was reverse-transcribed using the
SYBR PrimeScript RT-PCR kit II (Takara Bio Inc., Otsu,
Shiga, Japan) for first-strand cDNA synthesis using 2.5 μM
oligonucleotides primer and 5 μM random hexamer for the
priming method according to the manufacturer’s recommen-
dations. The first strand cDNA synthesis was started with the
incubation of the transcription mixture at 37 °C for 30 min, to
begin the reverse transcriptase reaction. Finally, the Prime
Script Reverse Transcriptase was inactivated by heating the
reaction mixture for 5 s. at 85 °C. Each RNA sample was
controlled for genomic DNA contamination by incubation
without the addition of reverse transcriptase into the cDNA
synthesis mixture. All cDNA samples were stored at −20 °C
and diluted with RNase and DNase free water before being
used as a template in the RT-qPCR (Reverse Transcriptase
quantitative Real-Time Polymerase Chain Reaction) analysis.
qPCR
Quantitative PCR was performed using the MxPro 3005P
apparatus (Stratagene, LaJolla, CA, USA) and the SYBR
Table 1 The study group and sub-cohorts clinical and genetic characteristics
a) Study group and sub-cohorts HDG n029 CG n028 b) HDG sub-cohorts HDG
Gender-cohort CAG–cohort
Female n016 n022 CAG number repeats
Male n013 n06 Mean value (SD) 45 (±15.0)
Age-cohort CAG1: 38–41 n09
Age (years) 46 40 CAG2: 42–44 n010
Mean value (SD)* (±15.0) (±15.0) CAG3: 46–81 n010
Age1: ≤35 n08 n012 TFC-cohort
Age2: 36–55 n015 n011 TFC (score in points)
Age3: ≥ 56 n06 n05 Mean value (SD) 9.7 (±3.1)
BMI-cohort TFC1: 1–8 n07
BMI (kg/m2) 23.8 23.2 TFC2: 9–10 n09
Mean value (SD) (±4) (±4.4) TFC3: 11–13 n013
BMI1: up to 18.4 (underweight) n02 n01 UHDRS-cohort
BMI2: 18.5–24.9 (standard) n017 n019 UHDRS (score in points)
BMI3: 25.0–29.9 (overweight) n06 n07 Mean value (SD) 38.5 (±24.3)
BMI4: 30.0–34.9 (obesity) n04 n01 UHDRS1: 1–
8 (presymptomatic)
n06
CC-cohort UHDRS2: 22–31 n05
Calf circumference CC (cm) 36.0 36.7 UHDRS3: 36–43 n08
Mean value (SD) (±3.6) (±3.1) UHDRS4: 45–55 n06
CC1: 27–30 n04 n00 UHDRS5: 61–91 n05
CC2: 31–35 n06 n012 HD disease duration (dd)-cohort
CC3: 36–38 n014 n010 HD duration period (years)
CC4 HDG/CG: 39–41/39–45 n05 n06 Mean value (SD) 6.3 (±4.7)
MNA-cohort HD dd1; 0 (presymptomatic) n06
MNA (score in points) 11.1 12.6 HD dd2; 1–5 n06
Mean value (SD) (±2.0) (±1.3) HD dd3; 6–10 n012
MNA1: 0–7 (malnourished) n04 n02 HD dd4; 11–15 n05
MNA2: 8–11 (risk of malnutrition) n010 n05
MNA3: 12–14 ( normal nutritional status) n015 n021
SD* standard deviation
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Premix Ex TaqTM II (Takara Bio Inc., Otsu, Shiga, Japan).
The PCR Mix solution was previously made using the
974.68 μl SYBR Premix, 1031.32 μl RNase and DNase
free water, and the 106 μl diluted template contained
400 ng of cDNA. The single PCR mix reaction volume
was 20 μl. Gene expression analysis was conducted with
the StellARray™ Gene Expression System (Lonza,
Walkersville, MD, USA), a type of qPCR array, with previ-
ously optimized primer concentrations applied into the 96
wells plates. Thermocycling conditions were set as follows:
an initial PCR mix activation was for 2 min. at 50 °C, the
next polymerase activation step was for 15 s. at 95 °C, then
40 cycles of 15 s. at 95 °C (template denaturation) and
1 min. at 60 °C (for annealing and elongation). A dissocia-
tion protocol with a gradient from 95 °C to 55 °C and to 95 °C
was used for each primer pair to verify the specificity of the
RT-qPCR reaction and the absence of primer-dimer control. In
addition, each PCR reaction included a reverse transcription
negative control to check for potential genomic DNA contam-
ination. Reagent contamination was also detected by a reac-
tion mix without template.
The panel of 95 genes, including normalizers, was previ-
ously selected for this study. The gene panel focused on
several pathways involved in energy metabolism (ATP pro-
duction) such as: glycolysis/Krebs cycle, electron transport
chain, mitochondria biogenesis and construction, BCAA
metabolism, transcription factors related to energy produc-
tion, cell cycle, cell stress/immune response and other cel-
lular pathways (Table 2).
An initial analysis was performed using the MxPro
3005P system software for determining the Ct (cycle thresh-
old) value after threshold assessment. The relative transcrip-
tion level was calculated based on ΔΔCt type of analysis
using the 2−ΔΔCt method in order to Fold Change (FC)
value determination between compared groups. The data
obtained after qPCR was analyzed by Global Pattern
Recognition, statistical software (GPR; https://array.bhbio.
com/BHB/GUI/AP/GPR.aspx). Normalization to 18S rRNA,
was used as internal control, and 9 additional genes normal-
izers simultaneously distinguished by GPR software analy-
sis were performed for each gene tested (Akilesh et al.
2003). The GPR algorithm allows the detection of signifi-
cant changes in gene expression patterns by comparing the
expression of each gene to every other gene in the array.
Significant changes are identified and ranked providing
relative normalization in qPCR experiments.
Statistical methods and calculations
A normal distribution of analytical results was verified and
confirmed. Then the t-Student’s test for differences between
HDG and CG was preformed. The GPR was used to deter-
mine the gene transcript level changes for the HDG with
reference to the CG (calibrator) using cycle threshold (Ct)
values obtained for all the genes tested. The GPR FC value
was calculated for each gene tested. FC with p≤0.05 was
defined as statistically significant. For all the genes tested in
the distinguished cohorts, several comparisons were per-
formed in order to screen for statistical significance in FCs.
The statistically significant FCs across sub-cohorts were ana-
lyzed by the Kruskal Wallis (Chi2) test and compared using
the Mann–Whitney U test - (Table 3a–i). The Spearman’s
coefficient was calculated to verify the correlation for analyt-
ical results with gene transcription level changes expressed by
FC (in the sub-cohorts), (Tables 4 and 5). SPSS v. 19.0
software (SPSS Inc., USA) and Statistica v. 9. software,
(StatSoft Inc, USA) were used for statistical calculations.
Results
Analytical tests
Comparison between analytical test results in both HDG and
CG was performed. Apart from cholesterol, HDL and LDL
levels in HDG, and HDL in CG, all other values of the
analytical test results in both groups did not exceed the
range of reference values. The cholesterol and LDL levels
were slightly higher (~210.1 and 131.6 respectively) in
HDG than in the control (198.7 and 119.4 respectively),
but not significant in the t-Student test. Total proteins, β2
fraction levels, alfa-1 globulins level and FT3 level were
significantly different between the CG and HDG, but were
within the range of reference values. Positive significant
correlations in the HGD among the HGB, HCT, ESR,
CRP MNA, MHCH levels as well as lymphocytes amount
and BMI were found. In the CG, a significant positive
correlation between CC and WBC and also BMI and CRP
was obtained (Table 5).
The relations between HD defining parameters,
anthropometric tests and MNA score
Correlations among clinical HD defining parameters, such as:
TFC, disease duration and CAG repeats number in the larger
allele and BMI, CC and MNA score were calculated based on
the Spearman’s coefficient factor analysis (Table 4). The sta-
tistically significant positive correlations were found between
the age of subjects and the age of HD onset (R00.718; p<
0.01) and between the calf circumference and TFC score (R0
0.386; p00.039) and also between MNA and TFC score (R0
0.525; p00.003). Results of these correlations indicate that as
HD progresses, the calf circumference and MNA score
decreases. A negative correlation was only found between
the age of HD subjects and the number of CAG repeats in
the larger allele (R0−0.551; p00.002).
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Table 2 A list of genes tested in this study
Gene ID Gene Symbol Function
Glycolysis/Krebs cycle
1 50 ACO2a Aconitase 2, mitochondrial
2 226 ALDOA Aldolase A, fructose-bisphosphate
3 2597 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
4 3417 IDH1 Isocitrate dehydrogenase 1 (NADP+)
5 3939 LDHA Lactate dehydrogenase A
6 4967 OGDH Oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide)
7 5160 PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1
8 5163 PDK1 Pyruvate dehydrogenase kinase, isozyme 1
9 5223 PGAM1 Phosphoglycerate mutase 1 (brain)
Electron transport chain/ATP production/mitochondria biogenesis and construction
10 488 ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2
11 1327 COX4I1 Cytochrome c oxidase subunit IV isoform 1
12 10328 COX4NB COX4 neighbor
13 4513 COX2 Cytochrome c oxidase subunit II
14 1374 CPT1A Carnitine palmitoyltransferase 1A
15 4129 MAOB Monoamine oxidase B
16 6390 SDH Succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
17 7351 UCP2 Uncoupling protein 2 (mitochondrial, proton carrier)
18 7352 UCP3 Uncoupling protein 3 (mitochondrial, proton carrier)
BCAA metabolism
19 27034 ACAD8 Acyl-Coenzyme A dehydrogenase family, member 8
20 4329 ALDH6A1 Aldehyde dehydrogenase 6 family, member A1
21 549 AUH AU RNA binding protein/enoyl-Coenzyme A hydratase
22 587 BCAT2 Branched chain aminotransferase 2, mitochondrial
23 593 BCKDHA Branched chain keto acid dehydrogenase E1, alpha polypeptide
24 594 BCKDHB Branched chain keto acid dehydrogenase E1, beta polypeptide
25 10295 BCKDK Branched chain ketoacid dehydrogenase kinase
26 1629 DBT Dihydrolipoamide branched chain transacylase E2
27 1738 DLD Dihydrolipoamide dehydrogenase, E3
28 11112 HIBADH 3-hydroxyisobutyrate dehydrogenase
29 56922 MCCC1 Methylcrotonoyl-Coenzyme A carboxylase 1 (alpha)
30 64087 MCCC2 Methylcrotonoyl-Coenzyme A carboxylase 2 (beta)
Transcription factors related to the energy production
31 10891 PPARGC1A Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha
32 23082 PPRC1 Peroxisome proliferator-activated receptor gamma, coactivator-related 1
33 5465 PPARA Peroxisome proliferator-activated receptor alpha
34 5467 PPARD Peroxisome proliferator-activated receptor delta
35 5468 PPARG Peroxisome proliferator-activated receptor gamma
36 6506 SLC1A2 Solute carrier family 1 (glial high affinity glutamate transporter), member 2
37 6517 SLC2A4 Solute carrier family 2 (facilitated glucose transporter), member 4
38 7019 TFAM Transcription factor A, mitochondrial
Cell cycle/cell death/apoptosis/immune response
39 366 AQP9 Aquaporin 9
40 581 BAX BCL2-associated X protein
41 598 BCL2L1 BCL2-like 1
42 627 BDNF Brain-derived neurotrophic factor
43 834 CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)
44 836 CASP3 Caspase 3, apoptosis-related cysteine peptidase
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Table 2 (continued)
Gene ID Gene Symbol Function
45 839 CASP6 Caspase 6, apoptosis-related cysteine peptidase
46 841 CASP8 Caspase 8, apoptosis-related cysteine peptidase
47 1020 CDK5 Cyclin-dependent kinase 5
48 1211 CLTA Clathrin, light chain A
49 1213 CLTC Clathrin, heavy chain (Hc)
50 3309 HSPA5 Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa)
51 3329 HSPD1 Heat shock 60 kDa protein 1 (chaperonin)
52 8870 IER3 Immediate early response 3
53 9927 MFN2 Mitofusin 2
54 27030 MLH3 MutL homolog 3
55 2475 MTOR Mechanistic target of rapamycin (serine/threonine kinase)
56 4792 NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
57 5921 RASA1 RAS p21 protein activator (GTPase activating protein) 1
58 8767 RIPK2 Receptor-interacting serine-threonine kinase 2
59 7124 TNF-a Tumor necrosis factor (TNF superfamily, member 2)
60 608 TNFRSF17 Tumor necrosis factor receptor superfamily, member 17
61 7157 TP53 Tumor protein p53
62 7316 UBC Ubiquitin C
63 3093 UBE2K Ubiquitin-conjugating enzyme E2K (UBC1 homolog, yeast)
64 7345 UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Cell stress/Immune response
65 875 CBS Cystathionine-beta-synthase
66 948 CD36 CD36 molecule (thrombospondin receptor)
67 1639 DCTN1 Dynactin 1 (p150, glued homolog, Drosophila)
68 1843 DUSP1 Dual specificity phosphatase 1
69 3117 HLA-DQA1 Major histocompatibility complex, class II, DQ alpha 1
70 3576 IL8 Interleukin 8
71 3553 IL1B Interleukin 1, beta
72 8564 KMO KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)
73 6648 SOD2 Manganese superoxide dismutase
Other transcription factors
74 1386 ATF2 Activating transcription factor 2
75 1387 CREBBP CREB binding protein
76 1958 EGR1 Early growth response 1
77 9611 NCOR1 Nuclear receptor co-repressor 1
78 283131 NEAT1 Nuclear paraspeckle assembly transcript 1 (non-protein coding)
79 4899 NRF1 Nuclear respiratory factor 1
80 56731 SLC2A4RG SLC2A4 regulator
81 6667 SP1 Sp1 transcription factor
82 6874 TAF4 TAF4 RNA polymerase II, TATA box binding protein
83 6908 TBP TATA box binding protein
84 7052 TGM2 Transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)
85 9322 TRIP10 Thyroid hormone receptor interactor 10
Calcium modulated proteins and HD related genes
86 801 CALM1 Calmodulin 1 (phosphorylase kinase, delta)
87 805 CALM2 Calmodulin 2 (phosphorylase kinase, delta)
88 808 CALM3 Calmodulin 3 (phosphorylase kinase, delta)
89 51806 CALML5 Calmodulin-like 5
90 9001 HAP1 Huntingtin-associated protein 1
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Gene expression
In order to identify the transcription level changes between
HDG and CG three types of comparisons were performed in
this study, the first, between undifferentiated HDG and CG,
and the second, between HDG- and CG-cohorts, were both
differentiated according to gender, age, BMI, calf circum-
ference (CC) and Mini Nutritional Assessment (MNA). In
addition, HDG-cohorts differentiated according to CAG
number repeats, TFC, UHDRS and HD duration were com-
pared with undifferentiated CG. The first transcript levels
measurement in undifferentiated HDG (n029) and CG (n0
28) revealed a statistically significant GPR FCs (p<0.05) for
MAOB (3.07), TGM2 (1.8), SLC2A4 (1.64) BCKDK
(1.34), LDHA (−1.16) and BDNF (−2.11) (Fig. 1).
The HDG and CGwere stratified according to the following
characteristics: gender, age, BMI, CC, MNA and gene tran-
scription rates were compared. Significant changes in transcrip-
tion were detected between the various sub-cohorts (Table 1a).
Comparison of gender revealed significant FCs for 3 transcripts
(Table 3a): CD36, MAOB and SLC2A4. In the HDG the FCs
for CD36 andMAOBwere significantly higher in women than
in men (1.1 vs. −1.78; p<0.05) and (2.34 vs. 4.32; p<0.05)
respectively. This was in contrast to SLC2A4, where the FC
was higher in men (1.89 vs. 1.15; p<0.05). The age sub-cohort
comparison (Table 3b) between the HDG and CG based on the
GPR analysis showed significant FCs in 16 genes. The FCs
range across age1- to age3-cohorts showed a decrease of
CREBBP, SLC2A4RG and an increase of HSPA5, ATP2A2
in HDG. These changes were found in all three HDG age sub-
cohorts; however the FC ranges across the age sub-cohorts
were not statistically significant. The transcription changes of
IL8, MTOR, BCKDHA, BCKDHB, MLH3 and UCP2 genes
found across the age cohorts presented a FCs decrease together
with age increase. The increased level of mRNA transcripts
concerned RASA1, ACO2, UBE2K, HSPD1, PPARG and
CASP6was also found in the age2- and age3-cohorts regarding
the reduced level only in the age1-cohort.
The BMI-cohort was differentiated into four sub-cohorts
(BMI1-4) based on the BMI score ranges and reflected the
general classification of obesity (Table 1a). Due to the
relatively small number of HD and control subjects collect-
ed in the BMI1- and BMI4-cohorts, for the FCs calculation
the BMI1- and BMI2-cohorts and also BMI3- and BMI4-
cohorts were pooled. Analysis of transcription level changes
revealed 4 transcripts with statistically significant GPR FCs
including PPRC1, LDHA, SLC2A and MAOB (Table 3c).
The simultaneous increase of PPRC1 and decrease of
MAOB transcripts across the BMI-cohorts were statistically
significant according to the Kruskal Wallis test and appeared
together with the increase of BMI index value.
The CC-cohort (Table 3d) was differentiated based on the
size of calf circumference reflecting an increase of the
approximate muscular mass amount into four CC-cohorts
(Table 1a.). A comparison of the qPCR results between the
HDG and control yielded 5 transcripts FCs with p<0.05
based on GPR including an increase of IL8 transcript (from
−2.48 for CC1 up to 1.41 for CC3),MAOB transcript (from
3.72 for CC1 up to 4.16 for CC3), and a decrease of COX2
transcript (from −1.05 for CC1 up to −1.27 for CC3), and
TGM transcript (from 2.62 for CC1 up to 1.36 for CC4),
however COX2 FC ranges were not statistically significant.
The MNA-cohorts reflected a study group differentiation
performed on the basis of the nutrition status assessment
according to the MNA scale (Table 1a) (Rubenstein et al.
2001). Due to the relatively small number of healthy subjects
found in the MNA1-cohort, control MNA1 and 2-cohorts
(with MNA score 8–11) were pooled and used as a reference
for the MNA1- and MNA2-cohort GPR FC calculations
(Table 3e). The MNA-cohorts comparison between the HDG
and control showed only two significant FCs, namely in
BDNF andMAOB. The range of FC values for BDNF showed
a transcript level decrease from −1.56 for the MNA1 to −2.55
for theMNA3-cohort and an increase of theMAOB level from
3.86 in the MNA1 up to 8.15 for MNA2, but a decrease of this
gene transcript level in the MNA3 to 1.61.
The third type of the qPCR result analysis was performed
for HDG sub-cohorts differentiated by the CAG number
repeats, TFC, UHDRS motor scale assessment, the HD
duration period and compared to no varied CG in order to
Table 2 (continued)
Gene ID Gene Symbol Function
91 3092 HIP1 Huntingtin interacting protein 1
92 3064 HTT Huntingtin
Preliminary normalizers and genomic DNA control
93 3251 HPRT1
94 60 ACTB
95 100008588 18S rRNA
96 gDNA control
a Statistically significant gene transcripts changes obtained in this study were distinguished by the bold type
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identify a panel of gene transcript changes related to the HD
progress. Depending on the number of CAG repeats in
larger allele of HTT gene, the HDG was divided into
CAG1-3 cohorts (Table 1b). Significant FCs in 9 transcripts:
BDNF, IL8, PPRC1, PPARGC1A, TNF-α, DCTN1,
SLC2A4, TGM2 and MAOB were observed (Table 3f).
Across the CAG-cohorts, statistically significant FC range
changes were found only for the IL8, TNF-α and MAOB
transcripts, however, IL8 FC values simultaneously in-
creased together with the CAG number repeats in CAG1-
and CAG2-cohorts. The TNF transcript levels presented
almost the same level in the CAG1- and 2-cohorts (1.06
and 1.14 respectively), but significantly decreased up to
−1.34 in the CAG3-cohort and the FC range was statistically
significant. The increase of MAOB transcript level from
2.08 in the CAG1- into 4.19 in the CAG2- was simulta-
neously observed with the number of CAG repeats. The
highest decrease of the BDNF FCs value was observed in
the CAG2- (−2.85) in contrast to the CAG1 cohort (−2.09),
however the BDNF FC range across the CAG1-3 cohorts
was not statistically significant.
The TFC-cohorts reflected the stage of HD from functional
ability perspective (Table 1b) and corresponded to HD pro-
gression. HD subjects with the most advanced functional
decline were included in the TFC1-cohort (score: 1–8), the
TFC2-cohort contains intermediate stage (score: 9–10) and
the TFC3-cohort presymptomatic stage (score: 11–13). A
comparative TFC-cohorts analysis (Table 3g) showed a sta-
tistically significant GPR FC concerning 4 transcripts
(SLC2A4, CBS, TGM2 and MAOB). However Kruskal
Wallis only confirmed significance for CBS and MAOB and
showed the CBS FC decrease (from 1.55 in the TFC1- to
−1.29 in the TFC3-cohort) and the MAOB FC decrease (from
6.47 in the TFC1- up to 1.92 in the TFC3-cohorts). The
strongest increase of the CBS and MAOB FCs was found
among HD subjects with the most advanced HD-stage
(Table 3g).
Movement disorders may contribute to metabolic HD
patients’ status as well. Therefore UHDRSmotor scale assess-
ment was included in this analysis (Table 1b). The presymp-
tomatic mutation carriers were located in the UHDRS1-cohort
with the scores’ range (1–8) what is an equivalent of mild
motor symptoms. Subjects with most severe motor symptoms
were included to the next UHDRS2-5-cohorts. Highest scored
patients were included in the UHDRS5-cohort with the
UHDRS motor scores from 61 to 91. The FC results obtained
for the UHDRS (1–5)-cohorts showed 5 transcripts with sig-
nificant GPR FCs: IL8, HIP1, TGM2, SLC2A4 and MAOB.
The Kruskal Wallis test confirmed significance in 3 FCs: IL8,
HIP1 and MAOB (Table 3h).
The HD disease duration – cohort (dd) was differentiated
into 5 sub-cohorts, the HD dd1-cohort consisting of pre-
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from onset), HD dd3 (5–10 years from onset), HD dd4 (10–
15 years from onset), and HD dd5 (15–20 years from onset)
respectively (Table 1b). The qPCR results comprised 7 tran-
scripts with statistically significant FCs including IL8,
BDNF, AQP9, SOD2, SLC2A4, BCAT2, and MAOB
(Table 3i). The widest statistically significant FCs concerned
BDNF (from −1.66 to −3.6) and BCAT2 (from 1.85 to
−1.42) where a gradual decrease was observed and MAOB
(from 1.87 to 7.89) where a gradual increase was observed
following increase of HD duration.
To summarize, the first comparison results performed
between undifferentiated HD- and Control Groups revealed
6 transcript genes, including the increase of MAOB, TGM2,
SLC2A4, BCKDK and the decrease of LDHA and BDNF
transcripts amount (Fig. 1) with statistically significant FC.
After sub-cohort comparisons 34 gene transcripts were dis-
tinguished (Table 3a–i), including genes involved in:
– energy metabolism: ACO2, ATP2A2, COX2, LDHA,
MAOB, PPARG, PPARGC1A, PPRC1, UCP2;
– BCAA metabolism: BCAT2, BCKDHA, BCKDHB,
BCKDK;
– other types of cellular processes: AQP9, CREBBP,
BDNF, CASP6, CBS, CD36, DCTN1, HIP1, HSPA5,
HSPD1, IL8, MLH3, MTOR, RASA1, SOD2,
SLC2A4, SLC2A4RG, TGM2, TNF-α and UBE2K.
The widest FCs revealed in this study (Table 3a–i)
concerned 7 transcripts including: MAOB (min. 1.44; max.
8.15), IL8 (min. −2.48; max. 1.41), HIP1 (min. −1.66; max.
1.56), BDNF (min. −3.6; max.−1.28), SLC2A4 (min. 1.19;
Table 4 Spearman’s coefficient
correlation in HDG and parame-
ters related to Huntington
disease
R- Spearman’s coefficient corre-
lation value; There are presented
only statistically significant
correlations
HD – sub-cohorts HD - subjects
Age (years) BMI- (kg/m2) Calf circumference (cm) MNA -score
HD onset age -years R* 0.718 0.227 −0.029 0.081
P <0.01 0.236 0.879 0.677
CAG-repeats number R −0.551 −0.318 −0.341 −0.249
P 0.002 0.093 0.071 0.192
TFC score R −0.022 0.263 0.386 0.525
P 0.909 0.168 0.039 0.003
Table 5 Spearman’s coefficient correlation between analytical tests results determined for HDG and CG









Calf circumference (cm) MNA- score
WBC R* −0.054 0.163 0.209 0.135 −0.213 0.213 0.378 0.055
p 0.781 0.398 0.276 0.485 0.276 0.277 0.047 0.781
RBC R 0.329 0.436 0.227 0.111 0.009 0.040 0.101 0.139
p 0.081 0.018 0.235 0.567 0.964 0.839 0.608 0.482
HGB R 0.322 0.506 0.361 0.251 0.008 0.065 0.166 0.166
p 0.088 0.005 0.055 0.189 0.967 0.741 0.400 0.399
HCT R 0.334 0.439 0.305 0.087 0.004 −0.016 0.149 0.006
p 0.077 0.017 0.108 0.654 0.985 0.937 0.459 0.977
MCHC R 0.043 0.353 0.274 0.494 0.086 0.189 0.315 0.356
p 0.825 0.060 0.151 0.006 0.665 0.336 0.103 0.063
Lymphocytes R 0.031 0.220 0.116 0.440 −0.234 0.103 0.294 −0.091
p 0.875 0.252 0.549 0.017 0.231 0.601 0.130 0.646
ESR R 0.504 0.422 0.207 0.286 0.190 0.175 −0.048 −0.213
p 0.005 0.023 0.282 0.133 0.332 0.373 0.808 0.277
CRP R 0.230 0.511 0.331 0.151 0.079 0.408 0.361 −0.044
p 0.229 0.005 0.080 0.433 0.690 0.031 0.059 0.823
R- Spearman’s coefficient correlation value; p- value. There are presented only statistically significant correlations
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max. 2.7), TGM2 (min. 1.36; max. 2.61), LDHA (min. −1.27
max. −1.09).
Discussion
The number of CAG repeats in the larger allele is responsi-
ble for up to 73 % of the variability of HD onset age
(Langbehn et al. 2004). It is therefore important to find other
genetic and non-genetic factors such as gender, age, nutrition
state, lifestyle, diet, activity or several etc. responsible for the
remaining 27 % of variability. This study was designed to
identify possible metabolic biomarkers of HD at the gene
transcription level. The relatively small study cohort limits
the ability to achieve significant results; however, among the
95 genes tested, the transcription rate of 34 of them was
significantly changed in the HDG. Statistically significant
GPR FC values obtained after the comparison between undif-
ferentiated HDG and CG revealed an increased level of four
transcripts; MAOB, TGM2, SLC2A4 and BCKDK, and de-
creased levels of two transcripts; BDNF, LDHA, compared to
healthy subjects.
The most significant transcription changes found in this
study concerned the MAOB gene encoding monoamine ox-
idase B. The MAOB protein is an outer mitochondrial
membrane-bound enzyme that catalyzes the oxidative de-
amination of arylalkylamine neurotransmitters such as do-
pamine and serotonin and xenobiotic monoamines (Binda et
al. 2003). In this study, the MAOB FC levels were the
highest in the sub-cohorts of subjects with the most ad-
vanced HD level, such as the TFC1- (6.47), UHDRS motor5
(5.97) -cohorts, compared to the MAOB FC levels in the
subcohorts of presymptomatic HD subjects such as TFC3-
(1.92) and UHDRS motor1 (1.87) -cohorts. .It also showed a
gradual increase of the MAOB gene transcript level in the
course of HD duration from FC01.87 in the HD dd1 up to
FC07.89 in the HD dd4. Interesting alterations were also
found for theMAOB gene transcript across the BMI-cohorts.
The highest MAOB FC level was in the cohort of subject
with the lowest BMI (BMI1-cohort, FC04.43) in contrast to
the cohort with the highest BMI (BMI3-4 cohort, FC01.44).
While this study is the first description of increased levels of
theMAOB gene transcript outside the CNS in HD-subjects, an
abnormally high level of the MAOB activity has previously
been demonstrated in the putamen, basal ganglia and other
brain areas of HD subjects (Richards et al. 2011). Increased
MAOB levels have also been described in the plasma of
Alzheimer’s disease patients, howeverMAOB gene transcrip-
tion was also increased in the brain. Increases of brain MAOB
levels has also been shown in Parkinson’s disease as well as in
psychotics disorders, where it is accompanied by MAOB
polymorphism (Bergen et al. 2009; Emilsson et al. 2002;
Naoi and Maruyama 2009). MAOB inhibitors are often clin-
ically used in Parkinson’s disease to improve motor function
(Binda et al. 2003; Schapira 2010). In several neurodegener-
ative disorders, increased MAOB levels lead to neuronal
damage caused by the neurotransmitters disturbances and an
increase of the oxidative stress locally in specific brain regions
(Bergen et al. 2009).
The MAOB protein location in the outer mitochondrial
membrane can be related to a gradual increase of the MAOB
gene transcript level. Several mitochondrial abnormalities
have been revealed in HD cells, including a decreased mem-
brane resting potential, impaired calcium ion homeostasis, and
marked morphological abnormalities with derangement of the
mitochondrial matrix and cristae (Panov et al. 2002; Squitieri
et al. 2006) and these mitochondrial abnormalities caused by
mHTT can be recapitulated in normal lymphocytes treated
with a fusion protein composed of a peptide containing a
pathogenic polyglutamine tract (Panov et al. 2002). There is
also evidence from HD mouse models (YAC72) and from
cultured HD striatal neurons expressing endogenous mutant
huntingtin (STHdhQ111) that the mHTT protein associates
directly with the outer mitochondrial membrane (Choo et al.
2004). The direct relationship between the increase of the
MAOB transcription levels in blood cells and its gradual
increase concurrent with HD progression found in this study
suggest a possible link with HD pathology.
The next significant changes found in this study concern
the tissue transglutaminase 2 (TGM2, TG2). TGM2 is a
calcium sensitive multifunctional enzyme with guanosine tri-
phosphate signaling activity as well as transamidating activity
(Munsie et al. 2011), and is present in the cytosol and nuclear
fractions of the brain tissue (Cooper et al. 1999). It has
previously been shown that the polyglutamine expansion in
huntingtin results in cellular stresses including endoplasmatic
reticulum disruption, increased calcium levels and activation
























Fig. 1 A gene transcription level comparison between HDG (n029)
and CG (n028) based on q-PCR results obtained by Global Pattern
Recognition Software
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links (Munsie et al. 2011). In our study, an increase of the
TGM2 gene transcription was found in a basic comparison and
in some sub-cohorts analysis, including the CC-, CAG-, TFC-
and UHDRS-cohorts. An increased level of TGM2 was pre-
viously found in the HD brain and lymphocytes (Munsie et al.
2011), but in here that was confirmed only on the transcription
level. The TGM2 FCs value alterations found in the sub-
cohorts indicate a correlation between transcription changes
and HD progress, indicated by an increase of TGM2 transcript
level together with UHDRS-score and the number of CAG
repeats, and with a decrease of the TFC-score. Additionally,
the highest of TGM2 FCs values (2.61) was found in the CC1-
cohort with the smallest calf circumference diameter. Our data
confirms that the quantifiable TGM2 gene transcription alter-
ations in blood cells may be used as biomarkers for HD.
This study is the first to describe the increased level of
the SLC2A4 transcription in HD subjects with reference to
the control and also the transcript level increased across
CAG1-2, TFC1-2, UHDRS1-3cohorts together with the
HD progression (HD dd1-2). The SLC2A4 gene encodes
an insulin-sensitive glucose transporter 4 (GLUT4) with a
critical role in glucose homeostasis (Korgun et al. 2002).
The clinical meaning of the SLC2A4 transcript alteration in
the HD-progress is unknown so far and it needs further
study, but it’s potential as a biomarker in the monitoring of
the HD progress outside the CNS could be useful.
The comparison between HDG and CG also showed the
increase of the BCKDK (branched chain ketoacid dehydro-
genase kinase) transcript level (1.34), while the sub-cohorts
comparisons revealed the alteration of three other transcripts
(BCKDHA, BCKDHB, and BCAT2) encoding enzymes
involved in BCAA catabolism. BCKDK controls the catab-
olism of BCAA by branched-chain β-ketoacid dehydroge-
nase complex (BCKDC) regulation (Harris et al. 2004). An
increase of the BCKDHB transcript level was found only in
the age1-cohort (1.26), but across the age2-3-cohorts a
decrease both of the BCKDHA and BCKDHB transcripts
was found. The decrease of BCAA level and muscle mass,
described previously in HD (Mochel et al. 2007), might be
related also to the increased level of BCKDHA and BCKDHB
(α-ketoacid dehydrogenase E1, alfa- and beta polypeptide).
However the gene transcript changes involved in the BCAA
metabolism haven’t been found as statistically significant in
the CC- and BMI-cohorts. The regulation of BCKDC is
related to BCKDK and BCKD phosphatase (BCKDP) activity
and linked to BCKDC level. Skeletal muscles are considered
an initial site for BCAA catabolism because of a high activity
of BCAA aminotransferase (BCAT2), a mitochondrial en-
zyme, responsible for the first step of BCAA catabolism
(Brosnan and Brosnan 2006). In the HD dd1-cohort an in-
creased level (1.85-fold) of the BCAT2 gene transcript encod-
ing aminotransferase was found, however in the HD dd2-
cohort this transcript level has been decreased to −1.42-fold
and has remained on the decreased level together with the
disease duration. To clarify the BCAA metabolism disturban-
ces in HD further studies are needed on the cellular level with
cells derived from HD and healthy subjects.
The slight decrease of the LDHA gene transcript level
found in this study (−1.16) might reflect an impairment of
glycolysis by inhibition of lactate acid conversion to pyru-
vate. The lactate level elevation due to the lactate dehydro-
genase level decrease was previously described in the HD
brain tissue and other tissues (Milakovic and Johnson 2005).
A decrease of the LDHA gene transcript level was clearly
expressed across the BMI- and CC- cohorts with the lowest
LDHA transcript level (−1.23-fold) in the BMI1-cohort and
the CC2-cohort. The decrease of these transcript levels
seems to be deepening together with the lower BMI- and
CC-scores, reflected in lower body and muscle mass.
The strongest decrease found in this study concerned the
BDNF gene, encoding Brain-Derived Neurotrophic Factor
protein and was obtained in a basic comparison between the
HD and control as well as in the sub-cohorts. It was previ-
ously shown that the normal huntingtin protein positively
influences the BDNF level, which protects and stimulates
neuronal cells growth (Borrell-Pages et al. 2006). The stron-
gest decrease in BDNF transcript levels was obtained in the
CAG2-cohort (with 42–44 CAG repeats number) and in the
dd-2-cohort. The reduction of the BDNF level had previ-
ously been described on a protein and transcript level in HD
and also other neurodegenerative disorders, but a recent
study confirms the phenomenon in HD only (Zuccato et
al. 2011). Many contemporary studies indicate that mito-
chondrial dysfunction and oxidative stress play a crucial role
in the majority of neurogenerative diseases. Mitochondria
are the major source of intracellular reactive oxygen species
and are particularly vulnerable to oxidative stress. In addi-
tion, the impairment of mitochondrial function disturbs the
cellular energy homeostasis. PGC1α stimulates the mito-
chondrial biogenesis and respiration, and this study has
shown significant changes concerning two transcript levels,
PPARGC1A and PPARC1, which are involved in energy
metabolism. The FCs values showed a slight increase of
PPARGC1A (1.54) and decrease of PPARC1 (−1.43) simul-
taneously with an increase of the number of CAG repeats.
Additionally a decrease of the PPRC1 transcript level simul-
taneously occurred with the BMI decrease in the HDG when
compared to the CG. These results are in line with the early
energy deficits described in HD subjects, with the exception
of PPARGC1A transcript levels which have been previously
reported to decrease in HD (Strand et al. 2005; Weydt et al.
2006; Yoon et al. 2003). It is difficult to explain this phe-
nomenon, but the HD-subjects who participated in this
study had previously used a variety of diet supplements that
might have influenced these gene transcripts that regulate
energy metabolism on the transcription level. On the other
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hand, it has been proposed that aberrant transcriptional
regulation of nuclear-encoded mitochondrial genes may be
involved in HD pathogenesis.
The HD related metabolic changes suggested by this
study need to be confirmed in a larger cohort before they
can be considered HD specific biomarkers. The gene tran-
scription level expressed by FCs and presented in this pre-
liminary report indicates that it may be possible to select a
HD biomarker from nuclear blood cells. Also, multiple
analyses of gene transcript levels (sub-cohorts comparisons)
showed more statistically significant FCs than the general
comparison between the HDG and GC. This implies the
multiple impact of particular genes on energy production
and BCAA metabolism. The results of the study are prom-
ising both for the identification of biomarkers for HD and
also for determining potential pharmacological targets for
the improvement of these altered metabolic pathways.
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